#USA #Culver City #Prostate Cancer #Avenda Health #Unfold AI

Avenda Health's Unfold AI Now Covered by Medicare

In a significant development for prostate cancer care, Avenda Health's Unfold AI has been integrated into the Medicare Physician Fee Schedule across the West Coast and Mountain West regions, enhancing access to advanced cancer treatment. This move, which affects California, Arizona, Utah, Nevada, Oregon, Washington, and Idaho, marks a pivotal moment for both patients and healthcare providers, as it enables broader utilization of AI-guided prostate cancer diagnostic tools.

Unfold AI: Transforming Prostate Cancer Diagnosis

Unfold AI is a cutting-edge, FDA-cleared platform utilizing artificial intelligence to create personalized 3D cancer maps from a patient's specific health data, including blood tests, imaging, and biopsy results. By mapping the disease's extent, this tool not only aids in diagnosing prostate cancer with greater accuracy but also guides treatment planning. Research shows that Unfold AI significantly improves the rate at which physicians can identify tumorous areas, with the sensitivity rising from 37% to a remarkable 97%. Furthermore, it enhances predictions regarding the spread of cancer, achieving 92% accuracy, a notable improvement compared to traditional MRI techniques.

Medicare Coverage Expands Access

The recent inclusion of Unfold AI in the Physician Fee Schedule follows a series of milestones for Avenda Health, including the establishment of a Medicare reimbursement model in 2025. During this phase, physicians using the platform began to receive compensation, paving the way for its increased adoption among urologists and healthcare providers. With Medicare's new payment framework now in place, more practitioners are encouraged to integrate this innovative technology into standard care practices for prostate cancer patients.

Dr. Shyam Natarajan, CEO of Avenda Health, expressed pride in the expansion of Unfold AI, emphasizing its importance in enhancing treatment accuracy and ultimately improving patient outcomes. He stated, "Seeing Unfold AI's expanded reach... improves access for patients to advanced prostate cancer treatment planning, and it's especially impactful here in our region."

The Road Ahead for AI in Healthcare

Avenda Health's journey with Unfold AI is a testament to the growing recognition and integration of artificial intelligence in healthcare. Following its 2024 breakthrough Category III CPT code from the American Medical Association (AMA), the platform has gained momentum, ensuring that cutting-edge diagnostic tools become an integral part of prostate cancer care.

In conclusion, the expanded Medicare coverage for Unfold AI provides a clear pathway for healthcare providers across multiple states to harness this technology, ultimately resulting in improved diagnostic decision-making and treatment precision for prostate cancer patients. To learn more about Unfold AI and find providers, visit Avenda Health's website. This advancement not only redefines the standards of prostate cancer care but also sets a precedent for future innovations in the medical field.